Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Neuroendocrine Tumours
Interventions
DRUG

lanreotide (Autogel formulation)

120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.

Trial Locations (27)

15006

H. Juan Canalejo, A Coruña

20012

Int. Oncológico San Sebastián, San Sebastián

28006

H. de la Princesa, Madrid

28034

H. Ramón y Cajal, Madrid

28040

H. Clínico Univ. San Carlos, Madrid

28041

H. 12 de Octubre, Madrid

28911

H. Severo Ochoa, Madrid

36001

Consorcio H. de Pontevedre, Pontevedra

37007

H. Clínico de Salamanca, Salamanca

38320

H. Univ. de Canarias, Santa Cruz de Tenerife

39008

H. Marques de Valdecilla, Santander

46009

H. La Fe, Valencia

46014

H. Hospital General Universitario de Valencia, Valencia

46520

H. de Sagunto, Sagunto

48013

H. de Basurto, Bilbao

50009

H. Miguel Servet, Zaragoza

446017

"Hospital Universitario Dr. Peset", Valencia

03804

H. Virgen de los Lirios, Alcoy

03010

H. General Univ. de Alicante, Alicante

08916

H. Germans Trias i Pujol, Badalona

08025

H. Santa Creu i Sant Pau, Barcelona

08036

H. Clínic i Provincial, Barcelona

08208

Corporación H. Parc Tauli, Barcelona

08227

Consorci Sanitari de Terrassa, Barcelona

08906

H. General de Hospitalet, Barcelona

03203

H. General de Elche, Elche

07198

Fundación H. Son Llàtzer, Palma de Mallorca

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT00326469 - Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours | Biotech Hunter | Biotech Hunter